Loading...
AVTE logo

Aerovate Therapeutics, Inc.NasdaqGM:AVTE Stock Report

Market Cap US$77.7m
Share Price
n/a
1Y-86.6%
7D-2.9%
1D0%
Portfolio Value
​
View

Aerovate Therapeutics, Inc.

NasdaqGM:AVTE Stock Report

Market Cap: US$77.7m

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Aerovate Therapeutics (AVTE) Stock Overview

A biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. More details

AVTE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($78M)


AVTE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW498,716 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
498,716 investors already sharing narratives
View all narratives

Aerovate Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Aerovate Therapeutics
Historical stock prices
Current Share PriceUS$93.80
52 Week HighUS$884.98
52 Week LowUS$43.75
Beta0.95
1 Month Change5.93%
3 Month Change4.08%
1 Year Change-86.61%
3 Year Change-79.38%
5 Year Changen/a
Change since IPO-88.26%

Recent News & Updates

Recent updates

Analysis Article • Oct 01

Here's Why Aerovate Therapeutics (NASDAQ:AVTE) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jun 11

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Summary Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The global Pulmonary Arterial Hypertension market size is expected to reach $12.2 billion by 2032. Aerovate has been able to take what was achieved with oral Imatinib and convert it to a dry inhaled powder that can be used to treat pulmonary arterial hypertension. AV-101 can become standard of care for PAH, when added to background therapy for PAH patients, if it can be shown to be superior to Merck's Winrevair. Read the full article on Seeking Alpha
Analysis Article • May 24

Here's Why We're Watching Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Feb 09

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 17

We're Not Very Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jul 04

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Feb 28

Aerovate Therapeutics (NASDAQ:AVTE) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Aerovate Therapeutics...
Analysis Article • Jan 06

A Look At The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Key Insights Aerovate Therapeutics' estimated fair value is US$27.2 based on 2 Stage Free Cash Flow to Equity Current...
Analysis Article • Oct 14

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jul 01

Here's Why We're Not Too Worried About Aerovate Therapeutics' (NASDAQ:AVTE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jan 22

We Think Aerovate Therapeutics (NASDAQ:AVTE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 30

Companies Like Aerovate Therapeutics (NASDAQ:AVTE) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Shareholder Returns

AVTEUS BiotechsUS Market
7D-2.9%4.1%1.6%
1Y-86.6%41.1%18.6%

Return vs Industry: AVTE underperformed the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: AVTE underperformed the US Market which returned 7.7% over the past year.

Price Volatility

Is AVTE's price volatile compared to industry and market?
AVTE volatility
AVTE Average Weekly Movement3.2%
Biotechs Industry Average Movement10.3%
Market Average Movement7.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: AVTE has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: AVTE's weekly volatility has decreased from 15% to 3% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20184Tim Noyeswww.aerovatetx.com

Aerovate Therapeutics, Inc., a biopharmaceutical company, engages in the treatment of pulmonary arterial hypertension in the United States. Aerovate Therapeutics, Inc., was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Aerovate Therapeutics, Inc. Fundamentals Summary

How do Aerovate Therapeutics's earnings and revenue compare to its market cap?
AVTE fundamental statistics
Market capUS$77.68m
Earnings (TTM)-US$48.96m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.6x
P/E Ratio

Is AVTE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
AVTE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$48.96m
Earnings-US$48.96m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-59.12
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did AVTE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/04/29 20:30
End of Day Share Price 2025/04/28 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aerovate Therapeutics, Inc. is covered by 2 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vasiliana MoussatosWedbush Securities Inc.
Laura ChicoWedbush Securities Inc.